Fennec Pharmaceuticals (FENC)
NASDAQ:FENC
FENC Stock Chart & Stats
$6.79
-$0.02(-0.33%)
At close: 4:00 PM EST
$6.79
-$0.02(-0.33%)
Day’s Range― - ―
52-Week Range$5.65 - $10.45
Previous Close$6.08
Volume58.66K
Average Volume (3M)250.54K
Market Cap
$344.94M
Enterprise Value$243.62M
Total Cash (Recent Filing)$40.08M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)256.4
Beta1.47
Next Earnings
Aug 06, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding34,737,030
10 Day Avg. Volume467,003
30 Day Avg. Volume250,544
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)6.29
Price to Sales (P/S)4.86
P/FCF Ratio-15.03
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue4.76
Enterprise Value/Gross Profit5.16
Enterprise Value/Ebitda-42.63
Forecast
1Y Price Target
$15.50Price Target Upside128.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.27
Revenue Forecast (FY)$69.00M
Bulls Say, Bears Say
Bulls Say
Clinical Guideline Endorsement And Real‑world EvidenceInclusion of PEDMARK in prominent clinical guidelines alongside ongoing investigator‑sponsored and real‑world studies could strengthen clinical credibility and encourage wider clinician adoption.
Commercial Adoption ExpansionAnalysts observe accelerating uptake of PEDMARK among adolescent and young adult patients across multiple tumor types, indicating rising commercial demand beyond the pediatric population.
Profitability And Commercial ModelAnalyst expects the company may have reached profitability and to sustain it, supported by a lean commercial model, anticipated royalty receipts in Europe, and reduced interest expenses following debt redemption.
Bears Say
Partnership, Competition And IP UncertaintyUncertainties around partner relationships, potential competitive threats, and questions about intellectual property protection could undermine market share and long‑term commercial prospects.
Regulatory Approval RiskKey risks include failure to obtain approvals in additional territories, which could limit market access and constrain international revenue growth.
Sales And Uptake ShortfallAnalyst notes reported sales were below forecasts and warns that slower U.S. commercial uptake could delay profitability and weaken revenue momentum.
Fennec Pharmaceuticals News
FENC FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was $5.65 and its highest was $10.45 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is $344.94M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 71 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on May 14, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.044 by $0.054.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is 0.01.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 34,737,030 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.044. Following the earnings report the stock price went up 36.484%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in FENC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fennec Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (128.28% Upside)
$15.50 (128.28% Upside)
Blogger Sentiment
Bullish
FENC Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 11.1%
Last 30 Days ▲ 11.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.59%
12-Months-Change
Fundamentals
Return on Equity
-55.13%
Trailing 12-Months
Asset Growth
54.78%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
FENC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple material commercial and clinical positives: strong top-line acceleration (+73% YoY), meaningful operational traction from the Fennec HEARS hub (48% QoQ infusion increase, 80% conversion and adherence), expanded commercial reach (prescriber targets expanded from ~1,300 to >5,000) and growing clinical momentum via ISTs and ASCO visibility. Counterbalancing these positives are higher near-term operating expenses (~$14M in Q1, ~$50M expected for 2026 with front-loaded spend), some near-term cash seasonality with Q2 expected to be lower than Q1, and a missed German milestone from partner Norgine. Overall, the highlights and catalysts materially outweigh the lowlights, with management emphasizing that cash plus projected revenues should fund operations and that commercial investments are already showing early returns.View all FENC earnings summariesFENC Stock 12 Month Forecast
Average Price Target
$15.50
▲(128.28% Upside)
Technical Analysis
Satellos Bioscience
―
Helix BioPharma
―
―
Eupraxia Pharmaceuticals
―
ME Therapeutics Holdings, Inc.
―
Ownership Overview
10.24% Insiders
4.49% Mutual Funds
― Other Institutional Investors
79.43% Public Companies and
Individual Investors